Intech Biopharm Corporation (TPEX:6461)

Intech Biopharm Statistics

Total Valuation

Intech Biopharm has a market cap or net worth of TWD 2.89 billion. The enterprise value is 3.87 billion.

Market Cap	2.89B
Enterprise Value	3.87B

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Intech Biopharm has 162.92 million shares outstanding. The number of shares has increased by 6.01% in one year.

Current Share Class	162.92M
Shares Outstanding	162.92M
Shares Change (YoY)	+6.01%
Shares Change (QoQ)	+2.99%
Owned by Insiders (%)	1.05%
Owned by Institutions (%)	6.44%
Float	95.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25.10
PB Ratio	2.55
P/TBV Ratio	2.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-12.00
EV / Sales	33.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.42

Financial Position

The company has a current ratio of 1.71, with a Debt / Equity ratio of 1.34.

Current Ratio	1.71
Quick Ratio	1.24
Debt / Equity	1.34
Debt / EBITDA	n/a
Debt / FCF	-4.09
Interest Coverage	-8.66

Financial Efficiency

Return on equity (ROE) is -30.16% and return on invested capital (ROIC) is -7.38%.

Return on Equity (ROE)	-30.16%
Return on Assets (ROA)	-7.10%
Return on Invested Capital (ROIC)	-7.38%
Return on Capital Employed (ROCE)	-13.13%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	90
Asset Turnover	0.04
Inventory Turnover	2.15

Taxes

In the past 12 months, Intech Biopharm has paid 6.80 million in taxes.

Income Tax	6.80M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.73% in the last 52 weeks. The beta is -0.15, so Intech Biopharm's price volatility has been lower than the market average.

Beta (5Y)	-0.15
52-Week Price Change	-39.73%
50-Day Moving Average	18.99
200-Day Moving Average	20.91
Relative Strength Index (RSI)	40.58
Average Volume (20 Days)	120,610

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Intech Biopharm had revenue of TWD 115.23 million and -322.26 million in losses. Loss per share was -2.33.

Revenue	115.23M
Gross Profit	-98.19M
Operating Income	-300.26M
Pretax Income	-315.45M
Net Income	-322.26M
EBITDA	-212.06M
EBIT	-300.26M
Loss Per Share	-2.33

Balance Sheet

The company has 543.60 million in cash and 1.52 billion in debt, giving a net cash position of -974.17 million or -5.98 per share.

Cash & Cash Equivalents	543.60M
Total Debt	1.52B
Net Cash	-974.17M
Net Cash Per Share	-5.98
Equity (Book Value)	1.13B
Book Value Per Share	6.95
Working Capital	318.01M

Cash Flow

In the last 12 months, operating cash flow was -325.57 million and capital expenditures -45.62 million, giving a free cash flow of -371.19 million.

Operating Cash Flow	-325.57M
Capital Expenditures	-45.62M
Free Cash Flow	-371.19M
FCF Per Share	-2.28

Margins

Gross margin is -85.21%, with operating and profit margins of -260.57% and -279.67%.

Gross Margin	-85.21%
Operating Margin	-260.57%
Pretax Margin	-273.76%
Profit Margin	-279.67%
EBITDA Margin	-184.04%
EBIT Margin	-260.57%
FCF Margin	n/a

Dividends & Yields

Intech Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.01%
Shareholder Yield	n/a
Earnings Yield	-11.14%
FCF Yield	-12.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Intech Biopharm has an Altman Z-Score of 0.78 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.78
Piotroski F-Score	4